# US 2026/0285942 A1 · Peptide Having Affinity for Human Transferrin Receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0285942 A1
- Document ID: US20260285942A1
- Status: Published application
- Kind: A1
- Application number: 18/711,730
- Filed: 2022-11-18
- Published: 2026-09-24
- Earliest claimed: 2021-11-19
- Assignees: JCR Pharmaceuticals Co., Ltd.
- Applicants: Jcr Pharmaceuticals Co., Ltd.
- Inventors: Takashi Onouchi; Kenichi Takahashi
- Web page: https://patentgrep.com/patent/US20260285942A1

## CPC

- C07K 14/79: Transferrins, e.g. lactoferrins, ovotransferrins
- C12N 5/10: Cells modified by introduction of foreign genetic material
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 47/644: {Transferrin, e.g. a lactoferrin or ovotransferrin}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/46: from vertebrates
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/2881: {against CD71}
- C07K 16/32: against translation products of oncogenes
- C12N 9/14: Hydrolases (3)
- C12N 9/16: acting on ester bonds (3.1)
- C12Y 301/06013: Iduronate-2-sulfatase (3.1.6.13)
- C12Y 310/01001: N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
- A01K 2207/15: Humanized animals
- A01K 2217/072: maintaining or altering function, i.e. knock in
- A01K 2217/075: inducing loss of function, i.e. knock out
- A01K 2217/15: Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
- A01K 2227/105: Murine
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C12N 15/85: for animal cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The present invention relates, in one embodiment thereof, to a peptide having affinity for human transferrin receptor, which can be used for binding to any of compounds (a protein, a nucleic acid, a low molecular weight compound, and the like) that should be caused to function in the central nervous system (CNS), in order to allow the compound to pass through the blood-brain barrier, and the use of the peptide. The peptide is, for example, a peptide having the amino acid sequence selected from the group consisting of amino acid sequences set forth in SEQ ID NOs:3 to 7 and 55, or a mutant thereof.

## Claims

### Claim 1

(canceled)

### Claim at position 2

2: A human transferrin receptor affinity peptide selected from the group consisting of the following (1) to (6):
(1) a peptide having the amino acid of SEQ ID NO:3;
(2) a peptide having the amino acid sequence of SEQ ID NO:4;
(3) a peptide having the amino acid sequence of SEQ ID NO:5;
(4) a peptide having the amino acid sequence of SEQ ID NO:6;
(5) a peptide having the amino acid sequence of SEQ ID NO:7; and
(6) a peptide having the amino acid sequence of SEQ ID NO:55, wherein the peptide has the ability to pass through the blood brain barrier.

### Claim at position 3

-8. (canceled)

### Claim at position 4 (depends on 2)

9: The human transferrin receptor affinity peptide according to claim 2, wherein the human transferrin receptor affinity peptide has affinity for both an extracellular region of human transferrin receptor and an extracellular region of monkey transferrin receptor.

### Claim 10

(canceled)

### Claim at position 6 (depends on 9)

11: The human transferrin receptor affinity peptide according to claim 9, wherein a dissociation constant with the extracellular region of human transferrin receptor is 8×10−9 to 2×10−8.

### Claim 12

(canceled)

### Claim at position 8 (depends on 9)

13: The human transferrin receptor affinity peptide according to claim 9, wherein when the value of the dissociation constant with the extracellular region of human transferrin receptor is taken as 1, the value of the dissociation constant with the monkey transferrin receptor is 0.7 to 1.2.

### Claim at position 9

-17. (canceled)

### Claim at position 10 (depends on 2)

18: A human transferrin receptor affinity peptide-drug complex, wherein the human transferrin receptor affinity peptide according to claim 2 is linked to a drug.

### Claim at position 11 (depends on 18)

19: The complex according to claim 18, wherein the drug is any one of a different protein (A), a nucleic acid, or a low molecular weight compound.

### Claim at position 12 (depends on 2)

20: A fusion protein comprising:
the human transferrin receptor affinity peptide according to claim 2 and
a different protein (A).

### Claim at position 13 (depends on 20)

21: The fusion protein according to claim 20, wherein the human transferrin receptor affinity peptide is bound to the C-terminus of the different protein (A) directly or via a linker.

### Claim at position 14 (depends on 20)

22: The fusion protein according to claim 20, wherein the human transferrin receptor affinity peptide is bound to the N-terminus of the different protein (A) directly or via a linker.

### Claim at position 15

-26. (canceled)

### Claim at position 16 (depends on 20)

27: The fusion protein according to claim 20, wherein the different protein (A) is a cytokine, a growth factor, or an antibody medicine.

### Claim at position 17 (depends on 20)

28: The fusion protein according to claim 20, wherein the different protein (A) is selected from the group consisting of a brain-derived neurotrophic factor (BDNF), a nerve growth factor (NGF), a lysosomal enzyme, a ciliary neurotrophic factor (CNTF), a glial cell-derived neurotrophic factor (GDNF), a neurotrophin 3, a neurotrophin 4/5, a neurotrophin 6, a neuregulin 1, an erythropoietin, a darbepoietin, an activin, a basic fibroblast growth factor (bFGF), a fibroblast growth factor 2 (FGF2), an epidermal growth factor (EGF), a vascular endothelial growth factor (VEGF), an interferon α, an interferon β, an interferon γ, an interleukin 6, a granulocyte-macrophage colony-stimulating factor (GM-CSF), a granulocyte-colony-stimulating factor (G-CSF), a macrophage colony-stimulating factor (M-CSF), a tumor necrosis factor-α receptor (TNF-α receptor), a PD-1 ligand, a PD-L1, a PD-L2, an enzyme having an activity of degrading beta-amyloid, an anti-beta-amyloid antibody, an anti-BACE antibody, an anti-EGFR antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, an anti-HER2 antibody, an anti-TNF-α antibody, and an anti-CTLA-4 antibody.

### Claim at position 18 (depends on 20)

29: The fusion protein according to claim 20, wherein the different protein (A) is a lysosomal enzyme, and the lysosomal enzyme is selected from the group consisting of α-L-iduronidase, iduronate-2-sulfatase, acidic α-glucosidase, glucocerebrosidase, β-galactosidase, GM2 activator protein, β-hexosaminidase A, β-hexosaminidase B, N-acetylglucosamine-1-phosphotransferase, α-mannosidase, β-mannosidase, galactosylceramidase, saposin C, allylsulfatase A, α-L-fucosidase, aspartylglucosaminidase, α-N-acetylgalactosaminidase, acidic sphingomyelinase, α-galactosidase A, β-glucuronidase, heparan-N-sulfatase, α-N-acetylglucosaminidase, acetyl CoA α-glucosaminide N-acetyltransferase, N-acetylglucosamine-6-sulfate sulfatase, acidic ceramidase, amylo-1,6-glucosidase, sialidase, palmitoyl protein thioesterase-1, tripeptidyl peptidase-1, hyaluronidase-1, CLN1, and CLN2.

### Claim at position 19

-31. (canceled)

### Claim at position 20 (depends on 2)

32: A nucleic acid encoding the human transferrin receptor affinity peptide according to claim 2.

### Claim at position 21 (depends on 20)

33: A nucleic acid encoding the fusion protein according to claim 20.

### Claim at position 22

-36. (canceled)
